Velcade in MALT Lymphoma Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00373906|
Recruitment Status : Completed
First Posted : September 8, 2006
Last Update Posted : November 27, 2013
|Condition or disease||Intervention/treatment||Phase|
|MALT Lymphoma||Drug: Bortezomib (Velcade)||Phase 2|
The objectives of this study are to evaluate the effectivity and the safety of bortezomib in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation.
It is a phase II prospective single arm study with a target sample of 16 patients. 1.5mg/m2 Bortezomib is given intravenously on day 1,4,8,11 every three week, for a maximum of 8cycles.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial pf Bortezomib in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type|
- to evaluate the clinical potential of bortezomib
- to induce objective/histologic responses in patients with MALT-Lymphoma
- to evaluate the impact of bortezomib on progression free survival
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00373906
|Principal Investigator:||Markus Raderer, Prof||Department of Internal Medicine I|